Apheresis: Basic Principles, Practical Considerations and

More documents

Recommendations

Info

Abnormal Substances Removed From the Circulation by TPE 1) Paraproteins (Waldenstorm’s Macroglobulinemia) 2) Autoantibodies (Myasthenia Gravis, Goodpasture’s syn.) 3) Lipids (LDL in familial hypercholesterolemia; phynatic acid in refsum’s disease 4) Toxins or drugs (that are bound to albumin) 5) Circulating immune complexes (CIC) 6) Soluble mediators of inflammatory response (activated complement component, vasoactive substances)
Apheresis Procedural Elements (+ Practical Considerations): •Venous access •Replacement fluid •Normal/abnormal constituents removed •Anticoagulation •Patient history and medications •Frequency and number of procedures •Complications
Page 1 and 2: Apheresis: Basic Principles, Practi
Page 3: Objectives (Part 2) • Clinical ap
Page 6 and 7: Apheresis- Mechanism of Action •L
Page 8 and 9: Separate blood components is based
Page 10 and 11: Apheresis- Mechanism of Action
Page 12 and 13: Plasmapheresis/TPE: Fluid Dynamics
Page 15 and 16: Technology •Automated centrifugal
Page 17: Use of Apheresis (cont.) Therapeuti
Page 21 and 22: Venous Access *Apheresis require la
Page 23 and 24: Apheresis Procedural Elements (+ Pr
Page 25 and 26: Replacement Fluid *The primary func
Page 27 and 28: Comparison of Replacement Fluids Re
Page 31 and 32: Volume of Patient Plasma Exchanged
Page 33 and 34: Normal/abnormal Constituents Remove
Page 37 and 38: Anticoagulation
Page 39 and 40: Patient History and Medications •
Page 41 and 42: ACE inhibitors A.C.E. Inhibitor Ang
Page 45 and 46: Interval between Exchanges : Why we
Page 47 and 48: Complications 1) Hypotension S/S: l
Page 49 and 50: 4) Allergic reaction: Complications
Page 51 and 52: Journal of Clinical Apheresis 16:3,
Page 53 and 54: Blood/Plasma Volume Calculations
Page 55 and 56: TBV - Nadler’s Formula
Page 57 and 58: Estimated Blood Volume
Page 59 and 60: Treatment Dosage A “typical” or
Page 61 and 62: Hematopoietic Stem Cells Transplant
Page 63 and 64: HSCs Quantification: Why CD34 CD34
Page 65 and 66: In Steady State • HPCs circulatin
Page 67 and 68: Mobilization of PBSCs Hematopoieti
Page 69 and 70:
Hematopoietic Growth Factors - CD34
Page 71 and 72:
Hematopoietic Growth Factors - CD34
Page 73 and 74:
HPC Collections -Technical Aspects
Page 75 and 76:
Post Collection Donor Issues • Pl
Page 77:
Post Collection Donor Issues G-CSF
show all

Apheresis: Basic Principles, Practical Considerations and

Create successful ePaper yourself

Delete template?

Save as template?